Agile Therapeutics Stock Forecast, Price & News

Agile Therapeutics (NASDAQ:AGRX) Frequently Asked Questions

Is Agile Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agile Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Agile Therapeutics stock.
View analyst ratings for Agile Therapeutics or view top-rated stocks.

How has Agile Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Agile Therapeutics' stock was trading at $1.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AGRX stock has decreased by 71.0% and is now trading at $0.5621.
View which stocks have been most impacted by COVID-19.

Are investors shorting Agile Therapeutics?

Agile Therapeutics saw a drop in short interest in the month of October. As of October 15th, there was short interest totaling 1,430,000 shares, a drop of 42.6% from the September 30th total of 2,490,000 shares. Based on an average daily volume of 1,600,000 shares, the short-interest ratio is presently 0.9 days.
View Agile Therapeutics' Short Interest.

When is Agile Therapeutics' next earnings date?

Agile Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Agile Therapeutics.

How were Agile Therapeutics' earnings last quarter?

Agile Therapeutics, Inc. (NASDAQ:AGRX) issued its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. Agile Therapeutics had a negative trailing twelve-month return on equity of 231.16% and a negative net margin of 2,072.43%. During the same period last year, the firm earned ($0.18) earnings per share.
View Agile Therapeutics' earnings history.

What price target have analysts set for AGRX?

4 brokerages have issued 1 year target prices for Agile Therapeutics' stock. Their forecasts range from $1.03 to $6.00. On average, they expect Agile Therapeutics' stock price to reach $3.38 in the next year. This suggests a possible upside of 501.8% from the stock's current price.
View analysts' price targets for Agile Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Agile Therapeutics' key executives?

Agile Therapeutics' management team includes the following people:

• Al Altomari, Chairman & Chief Executive Officer
• Dennis P. Reilly, Chief Financial Officer & Senior Vice President (LinkedIn Profile)
• Charles S. Grass, Senior Director-Finance
• Paul Korner, Chief Medical Officer
• Robert G. Conway, Chief Supply Chain Officer & Senior Vice President

Who are some of Agile Therapeutics' key competitors?

Some companies that are related to Agile Therapeutics include CM Life Sciences III (CMLT), Paratek Pharmaceuticals (PRTK), Annovis Bio (ANVS), Inozyme Pharma (INZY), iBio (IBIO), Athenex (ATNX), Alzamend Neuro (ALZN), Mustang Bio (MBIO), 180 Life Sciences (ATNF), Infinity Pharmaceuticals (INFI), Frequency Therapeutics (FREQ), CorMedix (CRMD), Millendo Therapeutics (MLND), Seelos Therapeutics (SEEL) and TFF Pharmaceuticals (TFFP).
View all of AGRX's competitors.

What other stocks do shareholders of Agile Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agile Therapeutics investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Nabriva Therapeutics (NBRV), AcelRx Pharmaceuticals (ACRX), Micron Technology (MU) and Novavax (NVAX).

What is Agile Therapeutics' stock symbol?

Agile Therapeutics trades on the NASDAQ under the ticker symbol "AGRX."

Who are Agile Therapeutics' major shareholders?

Agile Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.58%), Millennium Management LLC (1.01%), Royal Bank of Canada (0.87%), Geode Capital Management LLC (0.75%), GSA Capital Partners LLP (0.63%) and Morgan Stanley (0.56%). Company insiders that own Agile Therapeutics stock include Alfred Altomari, Dennis Reilly, Jason Butch, Life Sciences Maste Perceptive and Perceptive Advisors Llc.
View institutional ownership trends for Agile Therapeutics.

Which institutional investors are selling Agile Therapeutics stock?

AGRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Morgan Stanley, Royal Bank of Canada, Citadel Advisors LLC, Dumont & Blake Investment Advisors LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Agile Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Agile Therapeutics stock?

AGRX stock was acquired by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, BlackRock Inc., and Summit Global Investments. Company insiders that have bought Agile Therapeutics stock in the last two years include Alfred Altomari, Dennis Reilly, Jason Butch, Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Agile Therapeutics or or view top insider-buying stocks.

How do I buy shares of Agile Therapeutics?

Shares of AGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agile Therapeutics' stock price today?

One share of AGRX stock can currently be purchased for approximately $0.56.

How much money does Agile Therapeutics make?

Agile Therapeutics has a market capitalization of $52.28 million and generates $750 thousand in revenue each year. The specialty pharmaceutical company earns $-51.85 million in net income (profit) each year or ($0.78) on an earnings per share basis.

How many employees does Agile Therapeutics have?

Agile Therapeutics employs 28 workers across the globe.

What is Agile Therapeutics' official website?

The official website for Agile Therapeutics is www.agiletherapeutics.com.

Where are Agile Therapeutics' headquarters?

Agile Therapeutics is headquartered at 101 POOR FARM ROAD, PRINCETON NJ, 08540.

How can I contact Agile Therapeutics?

Agile Therapeutics' mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company can be reached via phone at (609) 683-1880 or via email at [email protected].